Atara Biotherapeutics (ATRA) Other Non-Current Liabilities (2013 - 2026)

Atara Biotherapeutics has reported Other Non-Current Liabilities for 12 years, with the latest figure at $41.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 1226.32% year-over-year to $41.5 million; the trailing twelve-month figure through Mar 2026 stood at $41.5 million (up 1226.32% YoY), and the FY2025 full-year result was $42.4 million, up 8.76% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $41.5 million, down from $42.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $42.4 million in Q4 2025, with the low at $616000.0 in Q1 2022.
• Historically, Other Non-Current Liabilities has averaged $14.6 million across 5 years, with a median of $5.2 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 69.6% — and 2026, when it surged 1226.32%.
• Atara Biotherapeutics' Other Non-Current Liabilities stood at $5.6 million in 2022, then soared by 530.41% to $35.1 million in 2023, then increased by 11.2% to $39.0 million in 2024, then increased by 8.76% to $42.4 million in 2025, then slipped by 2.24% to $41.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $41.5 million (Q1 2026), $42.4 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.